- Home
- IIIV vs PRAX Comparison
IIIV vs PRAX Comparison
Compare IIIV & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- PRAX
- Stock Information
- Founded
- IIIV 2012
- PRAX 2015
- Country
- IIIV United States
- PRAX United States
- Employees
- IIIV N/A
- PRAX N/A
- Industry
- IIIV EDP Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- IIIV Technology
- PRAX Health Care
- Exchange
- IIIV Nasdaq
- PRAX Nasdaq
- Market Cap
- IIIV 589.9M
- PRAX 599.7M
- IPO Year
- IIIV 2018
- PRAX 2020
- Fundamental
- Price
- IIIV $26.75
- PRAX $37.10
- Analyst Decision
- IIIV Buy
- PRAX Strong Buy
- Analyst Count
- IIIV 7
- PRAX 10
- Target Price
- IIIV $29.57
- PRAX $116.50
- AVG Volume (30 Days)
- IIIV 264.5K
- PRAX 403.7K
- Earning Date
- IIIV 05-08-2025
- PRAX 05-02-2025
- Dividend Yield
- IIIV N/A
- PRAX N/A
- EPS Growth
- IIIV 4907.14
- PRAX N/A
- EPS
- IIIV 4.75
- PRAX N/A
- Revenue
- IIIV $241,651,000.00
- PRAX $8,122,000.00
- Revenue This Year
- IIIV $10.25
- PRAX N/A
- Revenue Next Year
- IIIV $12.64
- PRAX $789.73
- P/E Ratio
- IIIV $5.60
- PRAX N/A
- Revenue Growth
- IIIV 5.59
- PRAX 270.02
- 52 Week Low
- IIIV $18.75
- PRAX $26.70
- 52 Week High
- IIIV $29.80
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- IIIV 59.73
- PRAX 49.45
- Support Level
- IIIV $24.30
- PRAX $34.89
- Resistance Level
- IIIV $27.27
- PRAX $40.01
- Average True Range (ATR)
- IIIV 1.02
- PRAX 2.40
- MACD
- IIIV 0.04
- PRAX 0.35
- Stochastic Oscillator
- IIIV 88.26
- PRAX 37.25
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.